Search research articles
Contact Us
Filters
Showing results (131-140 of 208) with videos related to
Page
of 21
Sort By:
Journal of Translational Medicine
|
July 24, 2019
Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th-1 December 1st, 2018, Naples, Italy)
Paolo A Ascierto, Sanjiv S Agarwala, Gerardo Botti, et al.
Cancer
|
April 23, 2020
Pembrolizumab for the treatment of programmed death-ligand 1-positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study
Janice M Mehnert, Emily Bergsland, Bert H O'Neil, et al.
Journal for Immunotherapy of Cancer
|
December 1, 2019
Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge 2018" (28-29 November, 2018, Naples, Italy)
Paolo A Ascierto, Carlo Bifulco, Luigi Buonaguro, et al.
Cell
|
September 9, 2017
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy
Antoni Ribas, Reinhard Dummer, Igor Puzanov, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 13, 2021
Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma
Adi Diab, Scott S Tykodi, Gregory A Daniels, et al.
Oncotarget
|
August 7, 2019
Oncologist uptake of comprehensive genomic profile guided targeted therapy
Mary K Nesline, Paul DePietro, Grace K Dy, et al.
The Lancet. Oncology
|
October 12, 2012
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
Georgina V Long, Uwe Trefzer, Michael A Davies, et al.
Nature Communications
|
November 13, 2025
Multicellular immune ecotypes within solid tumors predict real-world therapeutic benefits with immune checkpoint inhibitors
Xuefeng Wang, Tingyi Li, Islam Eljilany, et al.
The Lancet. Oncology
|
January 23, 2016
Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial
Andrew J Armstrong, Susan Halabi, Tim Eisen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 17, 2021
Angiokines Associated with Targeted Therapy Outcomes in Patients with Non-Clear Cell Renal Cell Carcinoma
Andrew J Armstrong, Andrew B Nixon, Andrea Carmack, et al.
Page
of 21
Search research articles
Search
Showing results (131-140 of 208) with videos related to
Sort By:
Page
of 21
Journal of Translational Medicine
|
July 24, 2019
Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th-1 December 1st, 2018, Naples, Italy)
Paolo A Ascierto, Sanjiv S Agarwala, Gerardo Botti, et al.
Cancer
|
April 23, 2020
Pembrolizumab for the treatment of programmed death-ligand 1-positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study
Janice M Mehnert, Emily Bergsland, Bert H O'Neil, et al.
Journal for Immunotherapy of Cancer
|
December 1, 2019
Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge 2018" (28-29 November, 2018, Naples, Italy)
Paolo A Ascierto, Carlo Bifulco, Luigi Buonaguro, et al.
Cell
|
September 9, 2017
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy
Antoni Ribas, Reinhard Dummer, Igor Puzanov, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 13, 2021
Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma
Adi Diab, Scott S Tykodi, Gregory A Daniels, et al.
Oncotarget
|
August 7, 2019
Oncologist uptake of comprehensive genomic profile guided targeted therapy
Mary K Nesline, Paul DePietro, Grace K Dy, et al.
The Lancet. Oncology
|
October 12, 2012
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
Georgina V Long, Uwe Trefzer, Michael A Davies, et al.
Nature Communications
|
November 13, 2025
Multicellular immune ecotypes within solid tumors predict real-world therapeutic benefits with immune checkpoint inhibitors
Xuefeng Wang, Tingyi Li, Islam Eljilany, et al.
The Lancet. Oncology
|
January 23, 2016
Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial
Andrew J Armstrong, Susan Halabi, Tim Eisen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 17, 2021
Angiokines Associated with Targeted Therapy Outcomes in Patients with Non-Clear Cell Renal Cell Carcinoma
Andrew J Armstrong, Andrew B Nixon, Andrea Carmack, et al.
Page
of 21